Žilvinas Dambrauskas, Prof. dr. Abdominal, Bariatric Surgeon

More than 250 surgeries per year.

Licence

2007 MPL-09624 (Abdominal Surgeon), Kaunas, Lithuania

Work experience

From 2017 until now, Professor of the LSMU MA Surgery Clinic.

From 2007 until now, Abdominal Surgeon at Lithuanian University of Health Sciences Surgery Clinic.

2009 – 2017 Associate Professor of Surgery Clinic, Lithuanian University of Health Sciences.From 2015 – until now, Senior Researcher at the Surgical Gastroenterology Laboratory of the Digestive System Research Institute, Lithuanian University of Health Sciences.

2016 – now, Independent Expert on the COST Program.2012 – now, European Commission International Expert for Quality Assurance of University Medical Studies.

2009 – 2011 Expert in the National Project for Medical Studies “Preparation of the national concept of the European Credit Transfer and Accumulation System (ECTS): harmonization of credits and development and implementation of the methodology of study programs based on learning achievements.”

2003 – 2004 Research Associate in European Research Laboratory for Pancreatic Surgery and Molecular Biology, led by prof. H. Friess and prof. M. W. Buechler, Heidelberg University Hospital, Department of Surgery, Heidelberg, Germany.

2002 – 2007 Abdominal Surgery Residency at the Hospital of Lithuanian University of Health Sciences, Surgery Clinic (headed by Prof. J. Pundzius).

2000 – 2003 International Relations Coordinator, Kaunas Medical University, Faculty of Nursing.

Seminars and Internships

From 2007 Member of the Lithuanian Bariatric Surgery and International Federation for the Surgery of Obesity and Metabolic Disorders.

From 2015 Board Member at the European Digestive Surgery Organization.

From 2017 Education Committee Member at United European Gastroenterology Community.

Internship at Karolinska Hospital (Stockholm, Sweden).

Internship at Ghent University Hospital (Ghent, Belgium).

Internship at Heidelberg University Hospital (Heidelberg, Germany).

Internship at Sahlgrenska Hospital (Gothenburg, Sweden).

Internship at the Hospital of the Technical University of Munich (Munich, Germany).

Internship at Stanford University Hospital (Stanford, USA).

Scientific papers

1. Cesna V et al. Stimulated upregulation of HO-1 is associated with inadequate response of gastric and ovarian cancer cell lines to hyperthermia and cisplatin treatment. Oncol Lett. 2019 Aug;18(2):1961-1968. 
2. Gulla A et al. Heme Oxygenase-1 Polymorphism Is Associated With the Development of Necrotic Acute Pancreatitis Via Vascular Cell Adhesion Molecule-1 and the E-Selectin Expression Regulation Pathway Pancreas. 2019 Jul;48(6):787-791.
3. Lukosiute-Urboniene A et al. Human antigen R mediated post-transcriptional regulation of inhibitors of apoptosis proteins in pancreatic cancer. World J Gastroenterol. 2019 Jan 14;25(2):205-219. 
4. Bieliuniene E et al. Magnetic Resonance Imaging as a Valid Noninvasive Tool for the Assessment of Pancreatic Fibrosis. Pancreas. 2019 Jan;48(1):85-93. 
5. Cesna V et al. Narrow line between benefit and harm: Additivity of hyperthermia to cisplatin cytotoxicity in different gastrointestinal cancer cells. World J Gastroenterol. 2018 Mar 14;24(10):1072-1083. 
6. Jakstaite A et al. Upregulation of cugbp2 increases response of pancreatic cancer cells to chemotherapy. Langenbecks Arch Surg. 2016 Feb;401(1):99-111. 
7. Asting AG et al. Alterations in Tumor DNA Are Related to Short Postoperative Survival in Patients Resected for Pancreatic Carcinoma Aimed at Cure. Pancreas. 2016 Jul;45(6):900-7. 
8. Jakstaite A et al. HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer. World J Gastroenterol. 2015 Dec 14;21(46):13004-19. 
9. Gulla A et al. Heme oxygenase-1 gene promoter polymorphism is associated with the development of necrotizing acute pancreatitis. Pancreas. 2014 Nov;43(8):1271-6. 
10. Dambrauskas Z et al. Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin Cancer Res. 2005 May 15;11(10):3790-8.